TY - JOUR
T1 - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease
AU - Leeneman, Brenda
AU - Blommestein, Hedwig M.
AU - van Dongen-Leunis, Annemieke
AU - Algeri, Mattia
AU - Fibbe, Willem E.
AU - Oosten, Liesbeth
AU - Uyl-de Groot, Carin A.
AU - Thielen, Frederick W.
N1 - Funding Information: The HOVON 113 MSC trial was funded through the European Union's Horizon 2020 research and innovation program (grant agreement number: 643580) and the Dutch Cancer Society. Publisher Copyright: © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2023/8
Y1 - 2023/8
N2 - Background: Evidence regarding health-related quality of life (HRQoL) in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD) is lacking. Evaluating HRQoL was a secondary objective of the HOVON 113 MSC trial. Here we describe the outcomes of the EQ-5D-5L, EORTC QLQ-C30, and FACT-BMT for all adult patients who completed these questionnaires at baseline (i.e., before the start of treatment; n = 26). Methods: Descriptive statistics were used to describe baseline patient and disease characteristics, EQ-5D dimension scores and values, EQ VAS scores, EORTC QLQ-C30 scale/item and summary scores, and FACT-BMT subscale and total scores. Results: The mean EQ-5D value was 0.36. In total, 96% of the patients reported problems with usual activities, 92% with pain/discomfort, 84% with mobility, 80% with self-care, and 72% with anxiety/depression. The mean EORTC QLQ-C30 summary score was 43.50. Mean scale/item scores ranged from 21.79 to 60.00 for functioning scales, from 39.74 to 75.21 for symptom scales, and from 5.33 to 91.67 for single items. The mean FACT-BMT total score was 75.31. Mean subscale scores ranged from 10.09 for physical well-being to 23.94 for social/family well-being. Conclusion: Our study showed that HRQoL in patients with SR-aGvHD is poor. Improving HRQoL and symptom management in these patients should be a top priority.
AB - Background: Evidence regarding health-related quality of life (HRQoL) in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD) is lacking. Evaluating HRQoL was a secondary objective of the HOVON 113 MSC trial. Here we describe the outcomes of the EQ-5D-5L, EORTC QLQ-C30, and FACT-BMT for all adult patients who completed these questionnaires at baseline (i.e., before the start of treatment; n = 26). Methods: Descriptive statistics were used to describe baseline patient and disease characteristics, EQ-5D dimension scores and values, EQ VAS scores, EORTC QLQ-C30 scale/item and summary scores, and FACT-BMT subscale and total scores. Results: The mean EQ-5D value was 0.36. In total, 96% of the patients reported problems with usual activities, 92% with pain/discomfort, 84% with mobility, 80% with self-care, and 72% with anxiety/depression. The mean EORTC QLQ-C30 summary score was 43.50. Mean scale/item scores ranged from 21.79 to 60.00 for functioning scales, from 39.74 to 75.21 for symptom scales, and from 5.33 to 91.67 for single items. The mean FACT-BMT total score was 75.31. Mean subscale scores ranged from 10.09 for physical well-being to 23.94 for social/family well-being. Conclusion: Our study showed that HRQoL in patients with SR-aGvHD is poor. Improving HRQoL and symptom management in these patients should be a top priority.
KW - EORTC QLQ-C30
KW - EQ-5D-5L
KW - FACT-BMT
KW - graft-versus-host disease
KW - health-related quality of life
KW - patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85158999666&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/ejh.13987
DO - https://doi.org/10.1111/ejh.13987
M3 - Article
C2 - 37137484
SN - 0902-4441
VL - 111
SP - 240
EP - 246
JO - European journal of haematology
JF - European journal of haematology
IS - 2
ER -